Discover
Allergy/Immunology – Dr. Barry Dworkin
UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.
Update: 2022-03-29
Share
Description
Medical Mythbusting Commentary for March 29, 2022
Source:
New compound delivered in a nasal spray effectively treats delta variant infection in mice
Reference:
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Comments
In Channel
00:00
00:00
x
0.5x
0.8x
1.0x
1.25x
1.5x
2.0x
3.0x
Sleep Timer
Off
End of Episode
5 Minutes
10 Minutes
15 Minutes
30 Minutes
45 Minutes
60 Minutes
120 Minutes



